ProCE Banner Activity

Primary Hyperoxaluria: Pathophysiology, Diagnosis, and New RNAi Treatment Approaches

Clinical Thought

Stay at the forefront of primary hyperoxaluria treatment with this discussion on the science behind and latest advances in RNAi therapy.

Released: November 17, 2023

Expiration: November 16, 2024

Share

Faculty

David S. Goldfarb

David S. Goldfarb, MD, FASN, FNKF

Clinical Chief
Department of Nephrology
NYU Langone Health
Professor of Medicine & Physiology
NYU Grossman School of Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Disclosure

Primary Author

David S. Goldfarb, MD, FASN, FNKF

Clinical Chief
Department of Nephrology
NYU Langone Health
Professor of Medicine & Physiology
NYU Grossman School of Medicine
New York, New York

David S. Goldfarb, MD, FASN, FNKF: owner: Moonstone Nutrition Inc.; consultant/advisor/speaker: Alnylam, Arbor, Lilac Pharmaceuticals, Novo Nordisk, Synlogic; researcher: Novo Nordisk.